Unique dosing for new minocycline
The FDA has given the nod to Solodyn, the first minocycline productapproved for once-daily dosing in the treatment of inflammatorylesions of non-nodular moderate to severe acne vulgaris.Manufacturer Medicis claims that Solodyn is not bioequivalent toany other minocycline product and is the only extended-releaseminocycline in tablet form.
Unique dosing for new minocycline
The FDA has given the nod to Solodyn, the first minocycline product approved for once-daily dosing in the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. Manufacturer Medicis claims that Solodyn is not bioequivalent to any other minocycline product and is the only extended-release minocycline in tablet form. According to the company, Solodyn should be prescribed only for patients 12 years of age and older and has a unique dosage of 1 mg/kg/day. Full prescribing information can be accessed on-line at http://www.solodyn.com/.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
